Record Information |
---|
Version | 2.0 |
---|
Created at | 2024-09-10 18:54:16 UTC |
---|
Updated at | 2024-09-10 18:54:16 UTC |
---|
NP-MRD ID | NP0334560 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Caramel |
---|
Description | Ramipril, also known as altace or tritace, belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Ramipril is a drug which is used for the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [Fda label] to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]. Ramipril is a very strong basic compound (based on its pKa). In humans, ramipril is involved in ramipril action pathway. Ramipril is a burnt and sugar tasting compound. Caramel was first documented in 1998 (PMID: 9510492). Outside of the human body, (PMID: 10485736) (PMID: 11095026) (PMID: 11575208) (PMID: 12076194). |
---|
Structure | [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid | ChEBI | Altace | ChEBI | Ramiprilum | ChEBI | Tritace | ChEBI | (2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate | Generator | (2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid | Generator | (2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate | Generator | (2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate | Generator | (2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid | Generator | Almirall brand OF ramipril | HMDB | Delix | HMDB | Hoechst brand OF ramipril | HMDB | Monarch brand OF ramipril | HMDB | Zabien | HMDB | Aventis brand OF ramipril | HMDB | Carasel | HMDB | HOE 498 | HMDB | HOE-498 | HMDB | Triatec | HMDB | Vesdil | HMDB | Astra brand OF ramipril | HMDB | Promed brand OF ramipril | HMDB | Acovil | HMDB | AstraZeneca brand OF ramipril | HMDB | Aventis pharma brand OF ramipril | HMDB | Ramace | HMDB |
|
---|
Chemical Formula | C23H32N2O5 |
---|
Average Mass | 416.5106 Da |
---|
Monoisotopic Mass | 416.23112 Da |
---|
IUPAC Name | (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid |
---|
Traditional Name | ramipril |
---|
CAS Registry Number | Not Available |
---|
SMILES | [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC |
---|
InChI Identifier | InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1 |
---|
InChI Key | HDACQVRGBOVJII-JBDAPHQKSA-N |
---|
Experimental Spectra |
---|
|
| Not Available | Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | Not Available |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Dipeptides |
---|
Alternative Parents | |
---|
Substituents | - Alpha-dipeptide
- Alpha-amino acid ester
- N-acyl-l-alpha-amino acid
- N-acyl-alpha-amino acid
- N-acyl-alpha amino acid or derivatives
- Alpha-amino acid amide
- Alpha-amino acid or derivatives
- Pyrrolidine carboxylic acid
- Pyrrolidine carboxylic acid or derivatives
- N-acylpyrrolidine
- Fatty acid ester
- Aralkylamine
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Benzenoid
- Fatty acyl
- Tertiary carboxylic acid amide
- Pyrrolidine
- Amino acid or derivatives
- Carboxamide group
- Carboxylic acid ester
- Amino acid
- Azacycle
- Secondary aliphatic amine
- Carboxylic acid
- Organoheterocyclic compound
- Secondary amine
- Hydrocarbon derivative
- Amine
- Organopnictogen compound
- Organic oxygen compound
- Carbonyl group
- Organic oxide
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Cacciapuoti F, Capasso A, Mirra G, De Nicola A, Minicucci F, Gentile S: Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. Int J Cardiol. 1998 Jan 31;63(2):175-8. doi: 10.1016/s0167-5273(97)00294-5. [PubMed:9510492 ]
- Kleinert S: HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation. Lancet. 1999 Sep 4;354(9181):841. doi: 10.1016/s0140-6736(99)80027-0. [PubMed:10485736 ]
- Soergel M, Verho M, Wuhl E, Gellermann J, Teichert L, Scharer K: Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol. 2000 Nov;15(1-2):113-8. doi: 10.1007/s004670000422. [PubMed:11095026 ]
- Grima M, Anjuere J, Ingert C, Coquard C, Steger J, Barthelmebs M, Imbs JL: [Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats]. Arch Mal Coeur Vaiss. 2001 Aug;94(8):805-12. [PubMed:11575208 ]
- Warner GT, Perry CM: Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs. 2002;62(9):1381-405. doi: 10.2165/00003495-200262090-00016. [PubMed:12076194 ]
|
---|